Yuman He
State Key Laboratory Of Systems Medicine For Cancer
Shanghai, China
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Zeb1-controlled metabolic plasticity enables remodeling of chromatin accessibility in the development of neuroendocrine prostate cancer.
Journal: Cell death and differentiation
Published: October 13, 2023
ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers.
Journal: The Journal of clinical investigation
Published: January 10, 2023
IL-1β Is an Androgen-Responsive Target in Macrophages for Immunotherapy of Prostate Cancer.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: November 23, 2022
Zeb1 sustains hematopoietic stem cell functions by suppressing mitofusin-2-mediated mitochondrial fusion.
Journal: Cell death & disease
Published: January 18, 2022
TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer.
Journal: Oncogene
Published: November 23, 2021
Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer.
Journal: Nature cancer
Published: March 18, 2021
A novel mouse model for liver metastasis of prostate cancer reveals dynamic tumour-immune cell communication.
Journal: Cell proliferation
Published: February 02, 2021
Identification of a Zeb1 expressing basal stem cell subpopulation in the prostate.
Journal: Nature communications
Published: January 20, 2019
Last Updated: 09/26/2026